SG11201908679QA - Isomerically pure 18f-labelled tetrahydrofolates - Google Patents
Isomerically pure 18f-labelled tetrahydrofolatesInfo
- Publication number
- SG11201908679QA SG11201908679QA SG11201908679QA SG11201908679QA SG 11201908679Q A SG11201908679Q A SG 11201908679QA SG 11201908679Q A SG11201908679Q A SG 11201908679QA SG 11201908679Q A SG11201908679Q A SG 11201908679QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- labelled
- pct
- isomerically pure
- tetrahydrofolates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT omit VIII °nolo olo X111011101011 0 101111111 ow (10) International Publication Number WO 2018/172243 Al (51) International Patent Classification: CO7D 475/04 (2006.01) CO7B 59/00 (2006.01) A61K 31/519 (2006.01) (21) International Application Number: PCT/EP2018/056806 (22) International Filing Date: 19 March 2018 (19.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17161884.6 20 March 2017 (20.03.2017) EP (71) Applicant: MERCK PATENT GMBH [DE/DE]; Frank- furter Strasse 250, 64293 Darmstadt (DE). (72) Inventors: MOSER, Rudolf; Lahnhalde 11, 8200 SCHAFFHAUSEN (CH). GROEHN, Viola; Bahnhofs- trasse 2, 8447 DACHSEN (CH). MUELLER, Cristi- na; Haldenstrasse 24, 5415 NUSSBAUMEN (CH). SCHIBLI, Roger; Schartenrainstrasse 42, 8093 BADEN (CH). AMETAMEY, Simon; Uetlibergstrasse 308, 8045 ZUERICH (CH). BOSS, Silvan; Rosentrasse 1, 2562 PORT (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: ' 6 E-4 with international search report (Art. 21(3)) 71' N (54) Title: ISOMERICALLY PURE 18F-LABELLED TETRAHYDROFOLATES 1-1 (57) : The present invention is directed towards isomerically pure 18 F-labelled (6S)-or (6R)-5-methyltetrahydrofolate radio- pharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an F-labelled N-heterocycle, for use in 18 \" diagnostic imaging of a cell or population of cells expressing a folate-receptor in vitro or in vivo or for use in monitoring of cancer or 0 inflammatory and autoimmune diseases and therapy thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17161884 | 2017-03-20 | ||
PCT/EP2018/056806 WO2018172243A1 (en) | 2017-03-20 | 2018-03-19 | Isomerically pure 18f-labelled tetrahydrofolates |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908679QA true SG11201908679QA (en) | 2019-10-30 |
Family
ID=58387756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908679Q SG11201908679QA (en) | 2017-03-20 | 2018-03-19 | Isomerically pure 18f-labelled tetrahydrofolates |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP3601288B1 (en) |
JP (1) | JP7204662B2 (en) |
KR (1) | KR102648945B1 (en) |
CN (1) | CN110431141B (en) |
AU (1) | AU2018237784B2 (en) |
CA (1) | CA3057042A1 (en) |
DK (1) | DK3601288T3 (en) |
EA (1) | EA201992180A1 (en) |
ES (1) | ES2893303T3 (en) |
IL (1) | IL269059B (en) |
PL (1) | PL3601288T3 (en) |
PT (1) | PT3601288T (en) |
SG (1) | SG11201908679QA (en) |
WO (1) | WO2018172243A1 (en) |
ZA (1) | ZA201906877B (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2150514T3 (en) | 2007-04-11 | 2019-02-18 | Merck & Cie | 18F-LABELED FOLATES |
PT2254890E (en) | 2008-02-20 | 2015-07-31 | Gnosis Spa | Process for the diastereoisomeric resolution of 5-methyltetrahydrofolic acid |
US20130034496A1 (en) | 2011-08-04 | 2013-02-07 | University Of Iowa Research Foundation | Positron emission tomography tracer |
WO2013167653A1 (en) * | 2012-05-08 | 2013-11-14 | Merck & Cie | 18f-labelled folate/antifolate analogues |
-
2018
- 2018-03-19 JP JP2019551384A patent/JP7204662B2/en active Active
- 2018-03-19 KR KR1020197030478A patent/KR102648945B1/en active IP Right Grant
- 2018-03-19 EA EA201992180A patent/EA201992180A1/en unknown
- 2018-03-19 PL PL18710887T patent/PL3601288T3/en unknown
- 2018-03-19 EP EP18710887.3A patent/EP3601288B1/en active Active
- 2018-03-19 SG SG11201908679Q patent/SG11201908679QA/en unknown
- 2018-03-19 CA CA3057042A patent/CA3057042A1/en active Pending
- 2018-03-19 CN CN201880018678.9A patent/CN110431141B/en active Active
- 2018-03-19 DK DK18710887.3T patent/DK3601288T3/en active
- 2018-03-19 AU AU2018237784A patent/AU2018237784B2/en active Active
- 2018-03-19 ES ES18710887T patent/ES2893303T3/en active Active
- 2018-03-19 PT PT187108873T patent/PT3601288T/en unknown
- 2018-03-19 WO PCT/EP2018/056806 patent/WO2018172243A1/en unknown
-
2019
- 2019-09-02 IL IL269059A patent/IL269059B/en unknown
- 2019-10-18 ZA ZA2019/06877A patent/ZA201906877B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20190130607A (en) | 2019-11-22 |
EP3601288A1 (en) | 2020-02-05 |
CA3057042A1 (en) | 2018-09-27 |
CN110431141A (en) | 2019-11-08 |
EA201992180A1 (en) | 2020-04-23 |
PL3601288T3 (en) | 2021-11-08 |
JP2020511477A (en) | 2020-04-16 |
PT3601288T (en) | 2021-07-20 |
AU2018237784B2 (en) | 2022-04-21 |
KR102648945B1 (en) | 2024-03-18 |
AU2018237784A1 (en) | 2019-11-07 |
US20200306390A1 (en) | 2020-10-01 |
DK3601288T3 (en) | 2021-07-05 |
CN110431141B (en) | 2022-12-30 |
IL269059B (en) | 2021-12-01 |
EP3601288B1 (en) | 2021-04-21 |
JP7204662B2 (en) | 2023-01-16 |
ES2893303T3 (en) | 2022-02-08 |
ZA201906877B (en) | 2021-06-30 |
IL269059A (en) | 2019-11-28 |
WO2018172243A1 (en) | 2018-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805072PA (en) | Nicotine powder delivery system | |
SG11201811640SA (en) | Multispecific antigen binding proteins and methods of use thereof | |
SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
SG11201909501TA (en) | Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
SG11201806512VA (en) | Copanlisib biomarkers | |
SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
SG11201907844TA (en) | Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders | |
SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
SG11201900043TA (en) | Antibody formulations | |
SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer | |
SG11201900336YA (en) | Radioligands for imaging the ido1 enzyme | |
SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy | |
SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies | |
SG11201811246RA (en) | Novel silybum marianum achene extract and uses thereof in dermatology and dermo-cosmetics | |
SG11201808540SA (en) | Methods of treatment for cholestatic and fibrotic diseases | |
SG11201909906QA (en) | Organic compounds |